Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
fda
4
×
alnylam pharmaceuticals
boston blog main
boston top stories
life sciences
national blog main
national top stories
boston
clinical trials
deals
hereditary transthyretin amyloidosis
new york blog main
new york top stories
patisiran
rna interference
san diego blog main
san diego top stories
akcea therapeutics
alexion pharmaceuticals
ambys medicines
amicus therapeutics
ampio pharmaceuticals
angelman syndrome
archive
athenex
biomarin pharmaceutical
biotech
bluebird bio
boehringer ingelheim
boulder/denver blog main
boulder/denver top stories
centers for medicare & medicaid services
chris collins
competitive generic therapy
cystic fibrosis
detroit blog main
detroit top stories
dicerna pharamceuticals
drugs
european medicines agency
What
drug
4
×
gene
4
×
fda
approves
disease
protein
therapy
administration
alnylam
approval
aren’t
bio
called
caught
causing
cells
children
designed
developers
dicerna
drugs
ema
employ
europe
eye
follows
food
genetic
harmful
help
hepatitis
hits
imminent
infants
intended
interference
issued
long
make
medicare
Language
unset
Current search:
gene
×
drug
×
fda
×
@xconomy.com
4 years ago
Roche to Pay Dicerna Pharma $200M to Team Up on Hepatitis B Drug
@slashgear.com
4 years ago
FDA approves $2.1m gene therapy for infants with rare genetic disease
@xconomy.com
5 years ago
RNAi Hits Europe as EMA Follows FDA, Approves Alnylam Drug
@xconomy.com
5 years ago
Bio Roundup: Medicare Drug Prices, FDA Moves, Gene Therapy News & More
